A phase 2 NASH study testing the GLP-1 injectable semaglutide—sold under the brand Ozempic as a weekly diabetes therapy—hit its primary goal, Novo said
Various pre-clinical and clinical studies have revealed the hepatoprotective effect of semaglutide in NASH and neuroprotective effect in Parkinson’s and
Only 10
19, 6
Indian drugmakers aiming to grab a slice of the burgeoning weight-loss treatment sales pie, both at home and abroad, have begun developing their own versions
Drug achieves NASH resolution but no fibrosis improvement Treatment with semaglutide — a glucagon-like peptide-1 (GLP-1) receptor agonist — may be an effective treatment for non-alcoholic steatohepatitis
Go to We conducted a 72-week, double-blind phase 2 trial involving patients with biopsy-confirmed NASH and liver fibrosis of stage F1, F2, or F3
Diabetes, insulin resistance, and obesity are responsible for the pathological manifestations of non-alcoholic steatohepatitis (NASH)
Now, preclinical data from Sagimet Biosciences hints that when it comes to treating NASH, blockbuster GLP-1 drugs like Novo Nordisk’s semaglutide may be more of an ally than a threat to pharma Earlier this month, the small French biotech Inventiva touted themselves as having won the first FDA breakthrough designation in NASH since Intercept grabbed the first Gilead Sciences and Novo Nordisk have announced positive results from a Phase II proof-of-concept trial evaluating combinations of Novo Nordisk’s semaglutide with Gilead’s cilofexor and/or firsocostat in participants with non-alcoholic steatohepatitis (NASH)
8 Novo Nordisk ® Investor presentation First three months of 2023 GLP-1 class expansion accelerates in the US in the first quarter of 2023 with volume growth across our portfolio NBRx: New-to-brand prescriptions; TRx: Total prescriptions; NN: Novo Nordisk; Scripts: Prescriptions; US: United States Note: Class growth calculated as Q1 2023 vs Q1 Novo Nordisk is one of the major contenders here, via its metabolic blockbuster semaglutide
Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company’s Annual Report 2016 and Form 20-F, which are both filed Phase 2 trial initiated with semaglutide in NASH ½ Victoza CV indication introduced to cardiologists Strategic priorities R&D achievements Commercial
This is despite the GLP-1 agonist failing to hit the key secondary endpoint of the study, looking at fibrosis resolution; Novo seems to believe that Merck & Co
We would like to show you a description here but the site won’t allow us
The study was done in more than 100 NASH patients with a fibrosis score of 2 or 3
Novo is continuing the molecule’s development in NASH in collaboration with Gilead